Sweden
· Delayed Price · Currency is SEK STO: BINV Company Description
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally.
Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4.
The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206.
The company was incorporated in 1996 and is based in Lund, Sweden.
| Country | Sweden |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Martin Welschof |
Contact Details
Address: The Gamma Building Lund, Skåne County 223 70 Sweden | |
| Phone | 46 4 62 86 85 50 |
| Website | bioinvent.com |
Stock Details
| Ticker Symbol | BINV |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015244520 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martin Welschof Ph.D. | President and Chief Executive Officer |
| Stefan Ericsson M.B.A. | Chief Financial Officer |
| Marie Moores M.Sc., R.G.N. | Chief Operating Officer |
| Kristoffer Rudenholm Hansson | Senior Vice President of Technical Operations |
| Björn Frendéus | Chief Scientific Officer |
| Cecilia Hofvander | Senior Director of Investor Relations |
| Dr. Andres McAllister | Chief Medical Officer |
| Ingrid Teige | Head of Preclinical Research |
| Sylvie Ryckebusch | Chief Business Officer |
| Dr. Ingunn Munch Lindvig | Senior Vice President of Regulatory Affairs |